Delineating the GRIN1 phenotypic spectrum
A distinct genetic NMDA receptor encephalopathy

ABSTRACT
Objective: To determine the phenotypic spectrum caused by mutations in GRIN1 encoding the NMDA receptor subunit GluN1 and to investigate their underlying functional pathophysiology.
Methods: We collected molecular and clinical data from several diagnostic and research cohorts. Functional consequences of GRIN1 mutations were investigated in Xenopus laevis oocytes.
Results: We identified heterozygous de novo GRIN1 mutations in 14 individuals and reviewed the phenotypes of all 9 previously reported patients. These 23 individuals presented with a distinct phenotype of profound developmental delay, severe intellectual disability with absent speech, muscular hypotonia, hyperkinetic movement disorder, oculogyric crises, cortical blindness, generalized cerebral atrophy, and epilepsy. Mutations cluster within transmembrane segments and result in loss of channel function of varying severity with a dominant-negative effect. In addition, we describe 2 homozygous GRIN1 mutations (1 missense, 1 truncation), each segregating with severe neurodevelopmental phenotypes in consanguineous families.
Conclusions: De novo GRIN1 mutations are associated with severe intellectual disability with cortical visual impairment as well as oculomotor and movement disorders being discriminating phenotypic features. Loss of NMDA receptor function appears to be the underlying disease mechanism. The identification of both heterozygous and homozygous mutations blurs the borders of dominant and recessive inheritance of GRIN1-associated disorders.

GLOSSARY
ASD = autism spectrum disorder; ID = intellectual disability; NMDAR = NMDA receptor; SNV = single nucleotide variant; VPA = valproate.

NMDA receptors (NMDARs) are tetrameric ligand-gated ion channels permeable to Na⁺, K⁺, and Ca²⁺, composed of 2 glycine binding GluN1 subunits and 2 glutamate binding GluN2/3 subunits (GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, GluN3B).¹⁻³

In contrast to GluN2/3 subunits, which each have specific spatial and temporal expression patterns throughout the CNS, GluN1 encoded by GRIN1 is a ubiquitous component of the receptor.⁴⁻⁵

Mutations of the NMDAR subunits are associated with a variety of different neurodevelopmental phenotypes,³ including intellectual disability (ID),⁶⁻⁸ epilepsy,⁹⁻¹³ and autism spectrum disorders (ASD), and different psychiatric diseases.¹⁴,¹⁵

While several studies have focused on the phenotypic spectrum of GRIN2A- and GRIN2B-associated disorders, little is known about the clinical presentations of individuals with GRIN1 mutations. We reviewed clinical data on individuals with GRIN1 mutations from different research cohorts as well as from diagnostic laboratories.

In addition, we reviewed available clinical and genetic information from previously reported patients with GRIN1 mutations. Nine heterozygous de novo mutations had previously been reported with rudimentary phenotypic information: 4 individuals were described with nonsyndromic and nonspecific ID (mental retardation, autosomal dominant 8, OMIM
RESULTS We identified 14 previously unreported patients with heterozygous GRIN1 mutations. In 13 individuals, the mutation was confirmed to be de novo, whereas in patient 22 parental samples were not available for segregation analysis. However, given that the particular mutation in patient 22 was recurrent in 2 other patients (patients 21 and 23) and absent in large control datasets, we concluded that the mutation is pathogenic and included this patient in our analysis. In addition to these 14 novel cases, we reviewed phenotypic data of all 9 previously reported cases and present additional clinical information on 4 of these patients. Thus, we were able to collectively review the clinical data of 23 patients (table 1). In addition to patients with de novo GRIN1 mutations, we identified 2 homozygous GRIN1 mutations segregating in 2 unrelated families with severe neurodevelopmental disorders (1.1–2 and 5.1–3). In both cases, family members carrying heterozygous GRIN1 variants were unaffected.

Phenotypes associated with heterozygous de novo GRIN1 mutations. Almost all patients carrying a de novo GRIN1 mutation presented with profound global developmental delay, usually already apparent in the neonatal period and resulting in severe intellectual disability (21/22; 95%). (table e-1, a and b) Patients usually never acquired the ability to walk and had absent or extremely limited verbal communication skills.

Of the 21 patients in whom information regarding muscular tone could be retrieved, 15 (71%) had severe truncal and initial appendicular hypotonia. Many patients developed corticospinal signs, such as hyperreflexia (6/21; 29%) or spasticity (6/21; 29%), consistent with a diagnosis of spastic quadriparesis. The majority of patients showed choreatic, dystonic, or dyskinetic movement disorders (14/23; 61%), including oculomotor abnormalities such as oculogyric crises (5/23; 22%). Nonspecific stereotypic movements were noted in 7/21 patients (33%).

A significant proportion of patients (16/23; 70%) had epilepsy. The epilepsy phenotype of GRIN1 mutation carriers was variable with respect to age at onset (day of life 1–11 years), seizure semiology (infantile spams, tonic and atonic seizures, hypermotor seizures, focal dyscognitive seizures, febrile seizures, generalized seizures, status epilepticus), and the associated EEG pattern (hypsarrhythmia, focal, multifocal and generalized spikes and waves). In addition to the variability of the epilepsy phenotype, the outcome relating to the control of seizures was variable: while at least 5 patients (5/16; 31%) had therapy-resistant epilepsy, 2 patients became seizure-free or had long periods of seizure freedom on valproate (VPA), whereas 2 additional patients responded well on a combination of topiramate, levetiracetam, and clobazam or the introduction of vigabatrin and clonazepam in addition to VPA. In most other epilepsy patients, clinical data were not available or seizures were not reported as a prominent phenotype (table e-3, a and b). Given this variability, the epilepsy phenotype of GRIN1 mutation carriers usually did not resemble specific forms of epileptic encephalopathies,
Abbreviations: CBD = Ca\(^{2+}\)-calmodulin binding domain; CVI = cortical visual impairment; Het = heterozygous; Hom = homozygous; ID = intellectual disability; LoF = loss of function; M1-4 = transmembrane domains; MD = movement disorder; NTD = aminoterminal domain; S1-2 = ligand binding domains; Sz = seizures.

Summary of phenotypic information of all published (a) and novel cases with GRIN1 mutations. The data comprise 23 patients with heterozygous proven (or likely) de novo mutations as well as 2 families (families 1 and 5) with homozygous GRIN1 mutations.

which is in contrast to GRIN2A- and some GRIN2B-associated disorders.\(^a\)\(^\text{-}^\text{13}\)

At least 8 GRIN1 patients were diagnosed with ASD or ASD-like features (8/23; 35%), acknowledging that the severe level of ID in most patients made a separate diagnosis of ASD challenging. This is in line with previous reports in GRIN2B-associated disorders\(^2\)\(^4\)\(^\text{;}^5\): 4 individuals presented with aggression and self-injurious behavior or disturbed pain perception (4/23; 17%). Eight patients (8/23; 35%) had nonspecified sleep disorders. Several patients had feeding difficulties (9/23; 39%), likely due to their underlying hypotonia and spasticity, requiring tube feeding in some patients. Several patients presented with cortical visual impairment or delayed visual maturation (5/23; 22%).

MRI findings were available for review in 19 patients, and nonspecific volume loss or atrophy was

<table>
<thead>
<tr>
<th>ID</th>
<th>Mutation (NM_007327)</th>
<th>Mutation (protein)</th>
<th>Zygosity</th>
<th>Origin</th>
<th>Protein domain</th>
<th>Functional effect</th>
<th>Consequence</th>
<th>Phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>c.649C&gt;T</td>
<td>p.Asp217Trp</td>
<td>Hom</td>
<td>Biparental</td>
<td>NTD</td>
<td>Increased Zn(^{2+}) inhibition</td>
<td>LoF (mild)</td>
<td>Severe ID, MD</td>
</tr>
<tr>
<td>1.2</td>
<td>c.649C&gt;T</td>
<td>p.Asp217Trp</td>
<td>Hom</td>
<td>Biparental</td>
<td>NTD</td>
<td>Increased Zn(^{2+}) inhibition</td>
<td>LoF (mild)</td>
<td>Severe ID, MD</td>
</tr>
<tr>
<td>2</td>
<td>c.1654A&gt;C</td>
<td>p.Ser549Arg</td>
<td>Het</td>
<td>De novo</td>
<td>Pre-M1</td>
<td></td>
<td>Severe ID, MD, Sz</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>c.1656C&gt;A</td>
<td>p.Asp552Glu</td>
<td>Het</td>
<td>De novo</td>
<td>Pre-M1</td>
<td></td>
<td>Severe ID, MD, Sz, CVI</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>c.1656C&gt;A</td>
<td>p.Asp552Glu</td>
<td>Het</td>
<td>De novo</td>
<td>Pre-M1</td>
<td></td>
<td>Severe ID, Sz</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>c.1666C&gt;T</td>
<td>p.Gln556e</td>
<td>Hom</td>
<td>Biparental</td>
<td>Pre-M1</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Fatal EE</td>
</tr>
<tr>
<td>5.1</td>
<td>c.1666C&gt;T</td>
<td>p.Gln556e</td>
<td>Hom</td>
<td>Biparental</td>
<td>Pre-M1</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Fatal EE</td>
</tr>
<tr>
<td>5.2</td>
<td>c.1666C&gt;T</td>
<td>p.Gln556e</td>
<td>Hom</td>
<td>Biparental</td>
<td>Pre-M1</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Fatal EE</td>
</tr>
<tr>
<td>6</td>
<td>c.1670C&gt;T</td>
<td>p.Arg217Trp</td>
<td>Hom</td>
<td>Biparental</td>
<td>Pre-M1</td>
<td>Increased activity of receptor</td>
<td>LoF (complete)</td>
<td>Severe ID, Sz, CVI</td>
</tr>
<tr>
<td>6</td>
<td>c.1679_1681dupGCA</td>
<td>p.Ser560dup</td>
<td>Het</td>
<td>De novo</td>
<td>Pre-M1</td>
<td>Reduced activity of receptor</td>
<td>LoF (complete)</td>
<td>Severe ID, Sz, CVI</td>
</tr>
<tr>
<td>7</td>
<td>c.1682G&gt;C</td>
<td>p.Gly618Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M2</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Severe ID</td>
</tr>
<tr>
<td>8</td>
<td>c.1685G&gt;C</td>
<td>p.Gly620Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M2</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Severe ID</td>
</tr>
<tr>
<td>9</td>
<td>c.1923G&gt;A</td>
<td>p.Gly641le</td>
<td>Het</td>
<td>De novo</td>
<td>M3</td>
<td>Severe ID, MD, Sz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>c.1933G&gt;T</td>
<td>p.Ala645Ser</td>
<td>Het</td>
<td>De novo</td>
<td>M3</td>
<td>Similar to wild-type</td>
<td>Unclear</td>
<td>Severe ID, Sz, CVI</td>
</tr>
<tr>
<td>11</td>
<td>c.1940A&gt;C</td>
<td>p.Tyr647Ser</td>
<td>Het</td>
<td>De novo</td>
<td>M3</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (intermediate)</td>
<td>Severe ID, Sz</td>
</tr>
<tr>
<td>12</td>
<td>c.1950C&gt;G</td>
<td>p.Arg650Lys</td>
<td>Het</td>
<td>De novo</td>
<td>M3</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (intermediate)</td>
<td>Severe ID, Sz</td>
</tr>
<tr>
<td>14</td>
<td>c.2443G&gt;A</td>
<td>p.Gly815Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (complete)</td>
<td>Severe ID, MD, Sz</td>
</tr>
<tr>
<td>15</td>
<td>c.2443G&gt;A</td>
<td>p.Gly815Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (complete)</td>
<td>Severe ID, MD, Sz</td>
</tr>
<tr>
<td>16</td>
<td>c.2443G&gt;A</td>
<td>p.Gly815Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (complete)</td>
<td>Severe ID, MD, Sz, CVI</td>
</tr>
<tr>
<td>17</td>
<td>c.2443G&gt;A</td>
<td>p.Gly815Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (complete)</td>
<td>Severe ID, MD, Sz, CVI</td>
</tr>
<tr>
<td>18</td>
<td>c.2444G&gt;T</td>
<td>p.Gly815Val</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Severe ID, MD, Sz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>c.2449T&gt;C</td>
<td>p.Phe817Leu</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (intermediate)</td>
<td>Severe ID</td>
</tr>
<tr>
<td>20</td>
<td>c.2449T&gt;C</td>
<td>p.Phe817Leu</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Reduced maximal agonist-inducible currents</td>
<td>LoF (intermediate)</td>
<td>ID, MD</td>
</tr>
<tr>
<td>21</td>
<td>c.2479G&gt;A</td>
<td>p.Gly827Arg</td>
<td>Het</td>
<td>De novo</td>
<td>M4</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Severe ID, MD</td>
</tr>
<tr>
<td>22</td>
<td>c.2479G&gt;A</td>
<td>p.Gly827Arg</td>
<td>Het</td>
<td>Unknown</td>
<td>M4</td>
<td>Nonfunctional</td>
<td>LoF (complete)</td>
<td>Severe ID, MD, Sz</td>
</tr>
<tr>
<td>23</td>
<td>c.2503G&gt;T</td>
<td>p.Arg844Cys</td>
<td>Het</td>
<td>De novo</td>
<td>CBD</td>
<td>Similar to wild-type</td>
<td>Unclear</td>
<td>Severe ID, MD, Sz</td>
</tr>
<tr>
<td>24</td>
<td>c.2503G&gt;T</td>
<td>p.Arg844Cys</td>
<td>Het</td>
<td>De novo</td>
<td>CBD</td>
<td>Similar to wild-type</td>
<td>Unclear</td>
<td>Severe ID, MD, Sz</td>
</tr>
</tbody>
</table>

Table 1 Phenotypes of cases with GRIN1 mutations

Neurology 86 June 7, 2016 2173
seen in 11/19 (58%) patients. These MRI findings were considered insufficient to explain the presence of quadriplegia or movement disorder seen in patients. Cortical atrophy was apparent already at young ages (e.g., cases 18 at 20 months and 25 at 3 years of age) without evidence for a significant age-dependent progression.

Two patients (2/21; 10%) had a marfanoid habitus, whereas several had normal stature or growth retardation or low body weight. Microcephaly was observed in 6/23 (26%) patients. Dysmorphic features, if present, were subtle. Deep-set eyes, which were previously reported as a common feature, could not be consistently seen in our patients.

While 21/22 patients had severe ID, one previously reported patient carrying a GRIN1 p.Glu662Lys mutation presented with a less severe phenotype. Patient 14 was able to walk independently at age 18 months and had speech delay with adequate first words at 9 months and 2-word phrases only at 5 years of age. Additionally, the patient did not present with any other comorbid conditions including epilepsy, movement disorder, and abnormalities of muscle tone or vision.

**GRIN1 mutations with recessive inheritance.** In a consanguineous family with ID and ASD, a homozygous GRIN1 p.Arg217Trp missense variant was found in 2 affected brothers. Both parents were healthy heterozygous carriers. The variant was predicted to be pathogenic (table e-2) and was absent in ExAC controls.

In a second consanguineous family, we identified a homozygous p.Gln556* truncation mutation in 3 siblings with severe neonatal epileptic encephalopathy. All 3 siblings died between 5 days of life and 5 months secondary to intractable seizures. Both parents were unaffected heterozygous carriers of the p.Gln556* mutation.

Among the 110 ExAC-annotated missense and 8 truncating GRIN1 variants, none was reported to be homozygous in 60,706 control samples.

**Spectrum and clustering of GRIN1 mutations.** All 16 different de novo mutations identified in the 23 novel and published cases are missense alterations and cluster within or in close proximity to the transmembrane domains forming the intrinsic ion channel pore of the receptor (figure 1). Interestingly, this region is widely spared from genetic variation in controls and shows a high level of conservation in different species (figure e-1). In contrast, there is extensive enrichment of reported single nucleotide variants (SNV) in controls in the N-terminal domain as well as the C-terminus of GRIN1. De novo mutations have not been observed in either domain. The reported mutations do not allow us to assess the genetic variability of S1 and S2 ligand binding sites. However, the S1 domain contains numerous and frequent SNV but no disease-causing mutations so far, whereas S2 showed less variability with only 2 nonrecurrent SNV but one mutation (figure 1). Moreover, this single mutation detected within S2 was associated with the mildest phenotype (patient 14) when compared to all other GRIN1 de novo mutations closely related to the transmembrane domains. Five de novo mutations have been detected recurrently in independent patients within our cohort (p.Asp552Glu, p.Gly815Arg, p.Phe817Leu, p.Gly827Arg, p.Arg844Cys).

The only mutation being far outside the transmembrane cluster is the p.Arg217Trp missense variant that was identified in a recessive family with unaffected heterozygous carriers.

**Functional investigations.** Ectopic expression of the GluN1 mutants with wild-type GluN2B subunits revealed that 4 of the mutants gave no response to up to 10 mM glutamate and glycine and were hence rated as nonfunctional (p.Gln556*, p.Gly618Arg, p.Gly620Arg, p.Gly827Arg; n = 10, each). For all other mutants, changes in maximal inducible currents and agonist affinities were examined. Four mutations (p.Pro557Arg, p.Tyr647Ser, p.Gly815Arg, p.Phe817Leu) resulted in a highly significant reduction

---

**Figure 1 Domains of GRIN1 and distribution of variants**

Signal peptide (SP), the extracellular N-terminal domain, and ligand binding sites (S1, S2), the transmembrane domains (M1-4), as well as the intracellular C-terminal domain (CTD) with the proximal Ca²⁺-calmodulin binding domain (CBD). De novo mutations (red) cluster within or in very close proximity to M1-4. In addition, this region is particularly spared from nonsynonymous genetic variation according to the ExAC browser (rare/single variants, gray; repeated/frequent variants, black). The 2 homozygous GRIN1 variants are marked in blue.

Coexpression of wild-type GluN1 with mutants GluN1 p.Tyr647Ser or p.Phe817Leu resulted in intermediate effects of agonist I\text{max} values (\( p < 0.01, n = 5 \)), supporting the idea of a negative impact of the substitutions on the function of hetero-oligomeric NMDARs (figure e-2c). Mutations p.Arg217Trp, p.Ala645Ser, and p.Arg844Cys generated functional receptors with agonist I\text{max} values (\( p > 0.05, n = 5 \)) similar to wild-type (data not shown). Functional analysis of the missense alteration GluN1 p.Arg217Trp in the N-terminal Zn\textsuperscript{2+}-binding domain with wild-type GluN2A subunits showed a significant increase in Zn\textsuperscript{2+} inhibition (figure e-2d), suggesting impaired activation in vivo due to increased tonic inhibition of GRIN1\textsuperscript{Arg217Trp}–GRIN2A receptors at physiologic concentrations of Zn\textsuperscript{2+}. However, functional analysis of mutations p.Ala645Ser and p.Arg844Cys revealed no significant effects on agonist I\text{max} values or affinity, suggesting that these 2 substitutions may alter NMDAR function through other mechanisms. For example, since the recurrent substitution p.Arg844Cys is located in the intracellular Ca\textsuperscript{2+}–calmodulin-binding domain, disturbed interactions with intracellular proteins may impair receptor function. Our analyses of de novo mutations are consistent with a dominant-negative effect resulting in a significant loss of receptor function.

**DISCUSSION** We reviewed 14 novel and 9 previously published individuals carrying heterozygous GRIN1 de novo mutations associated with neurodevelopmental phenotypes.

Profound developmental delay associated with severe ID and lack of speech development are predominant features, and muscular hypotonia leading to spastic quadriplegic cerebral palsy, hyperkinetic movement disorders including dystonia and chorea, and oculomotor abnormalities as well as cortical visual impairment appeared to be recurrent findings in individuals with GRIN1 encephalopathy. While some of these features can be seen in other genetic epileptic encephalopathies such as SCN2A and SCN8A encephalopathies (OMIM 613721, 600702), these findings are novel in the context of NMDAR encephalopathies. Seizures occurred in about two-thirds of cases. However, there was no obvious epilepsy pattern with respect to age at onset, seizure semiology, EEG features, or outcome. Furthermore, the frequency of epilepsy in GRIN1 patients may be an overestimate due to inclusion of a high proportion of epilepsy patients in the screening cohorts.

GRIN1 encodes GluN1 and autoantibodies primarily targeting an epitope within the N-terminal domain of GluN1 result in the increasingly recognized clinical entity of NMDAR encephalitis.\textsuperscript{22,23} NMDAR encephalitis is an acute paraneoplastic or parainfectious neurologic disorder where decay of NMDARs is considered to be the underlying pathomechanism, partially paralleling the pathophysiology of GluN1 loss of function seen in our patients with GRIN1 encephalopathy. While the acuity of the clinical presentation is vastly different, with NMDAR encephalitis presenting as an acute acquired condition while GRIN1 encephalopathy is a chronic neurodevelopmental disease, we would like to emphasize a shared group of symptoms including choreatic and dystonic movements, seizures, and sleep cycle dysregulation, which we observe in our patient cohort. Further research will be able to address the question whether the GRIN1 encephalopathy phenotype is specific enough to hypothesize a spectrum of NMDAR impairment in human disease.

GRIN1 de novo mutations cluster within or in direct proximity to the transmembrane domains of GRIN1 (figure 1). These regions are largely spared from genetic variation, underlining the crucial importance of these domains. The sole mutation outside this cluster is p.Arg217Trp, which appears to be only pathogenic when present homozygously and thus might mediate its effect through different effects compared to the heterozygous variants near the transmembrane domains.

All reported de novo mutations are missense variants. In contrast to GRIN2A and GRIN2B, heterozygous truncation of GRIN1 apparently does not result in a neurologic phenotype. Furthermore, both deletions encompassing GRIN1 as well as truncating or splice-site variants are seen in control databases, suggesting that haploinsufficiency in GRIN1, albeit rare, is tolerated in the human population.
In addition to 16 different heterozygous de novo mutations, we describe 2 recessive GRIN1 mutations. The homozygous loss-of-function p.Arg217Trp mutation segregated with severe ID, ASD, and movement disorders in 2 affected siblings in a consanguineous family (family 1), and a homozygous p.Gln556* truncation mutation was found in 3 individuals with fatal epileptic encephalopathy in family 5 (table 1). As the NMDAR obligatorily contains 2 GluN1 subunits, truncation or lack of both GRIN1 alleles would result in a knock-out and complete deprivation of the NMDAR. The almost continuous seizure activity with suppression-burst EEG and early death of all 3 affected siblings in family 5 underlines the vital role of GluN1 in NMDAR functioning.


The extent and nature of the loss of NMDAR function due to de novo GRIN1 mutations corresponded only marginally to the uniformly severe phenotypes. One possible explanation for this lack of genotype–phenotype correlation may be effects on the subunit composition or trafficking of the NMDAR that potentially lead to a shared secondary mechanism compensating GluN1 defects independent of the individual severity of the respective GRIN1 mutation eventually escaping visualization using standard artificial in vitro models.

Given the multiple observations of heterozygous de novo GRIN1 loss-of-function mutations, GRIN1-associated disorders are a recurrent cause of severe and complex neurodevelopmental disorders. Additionally, homozygous GRIN1 mutations segregating with severe phenotypes display phenotypic overlap with individuals carrying heterozygous GRIN1 de novo mutations. This observation blurs the borders of autosomal-dominant and autosomal-recessive inheritance. The constellation of severe ID and associated findings including prominent hypotonia, movement disorders, oculogyric crises, cortical visual impairment or blindness, absent speech, behavioral issues, sleep disorder, and seizures may allow for a phenotypic differentiation from other frequent forms of severe ID. Together with the catastrophic phenotype seen in homozygous truncation mutation carriers, our findings underscore the essential role of the NMDAR subunits in neurodevelopment.

AUTHOR AFFILIATIONS
From the Institute of Human Genetics (J.R.L., H.O.H., J.H.) and Integrated Research and Treatment Center (IFB) Adiposity Diseases (H.O.H.), University of Leipzig Hospitals and Clinics, Department of Neurophysiology and Neurosensory Systems (K.G., H.S., B.L.), Technical University Darmstadt, Germany; Division of Clinical Genetics (K.L.H.), Ambry Genetics, Aliso Viejo, CA; Division of Human Genetics (C.C.), University Children’s Hospital, Innsbruck, Austria; Folkhalsan Institute of Genetics (C.C.), Helsinki, Finland; INSERM (C.D., C.N., S.W.), U 1127, Sorbonne Universités, UPMC Université Paris 06, CNRS, UMR 7225, Institut du Cerveau et de la Moelle Épinière (ICM); Département de Génétique (C.D., C.N., D.H.) and Centre de Référence Épilepsies Rares, Epilepsie Unit (S.W.), AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Danish Epilepsy Centre (R.S.M., H.H.), Danmark, Institute for Regional Health Services (R.S.M., H.H.), University of Southern Denmark, Odense; Cologne Center for Genomics (CCG) (D.L., P.N., H.T.) and Center for Molecular Medicine Cologne (CMMC) (P.N.), University of Cologne, Germany; Psychiatric and Neurodevelopmental Genetics Unit (D.L.), Massachusetts General Hospital and Harvard Medical School, Boston; Program in Medical and Population Genetics (D.L.) and Stanley Center for Psychiatric Research (D.L.), Broad Institute of MIT and Harvard, Cambridge, MA; Department of Neuropediatrics (B.A.N.), University Medical Center Giessen and Marburg, Giessen, Germany; Division of Medical Genetics, University Medical Center Münster, Germany; Division of Medical Genetics, Department of Pediatrics, Pittsburgh University School of Medicine (G.L.A.), and Division of Child Neurology (A.G., D.S.R.), Children’s Hospital of Pittsburgh, PA; Department of Medical Genetics (V.B.), Children’s Hospitals and Clinics of Minnesota, Minneapolis, Minnesota; Institute of Clinical Genetics (D.B.), Klinikum Stuttgart, Germany; Canadian and European Center of Medical Genetics (C.R.J., P., D.M., E.F.) and Department of Clinical Neurosciences for Children, Women and Children’s Division (P.S.), Oslo University Hospital and University of Oslo, Norway; Division of Neurology (D.L.D., L.H.), The Children’s Hospital of Philadelphia, PA; Section of Clinical Genetics (E.S.D.), Carilion Clinic Children’s Hospital, Roanoke, VA; Department of Clinical Genetics (E.K.B., C.A.R., M.J.H.V.), Leiden University Medical Center, the Netherlands; The Center for Rare Childhood Disorders (V.N., K.R., N.B., I.S., R.R.), Translational Genomics Research Institute (TGen), Phoenix, AZ; Department of Medical Genetics (B.P.C.K., C.G.F.D.K.), UMCU, Utrecht, the Netherlands; Centro Hospitalar do Algarve (J.S., C.M.), Faro, Portugal; Neurogenetics Group, VIB-Department of Molecular Genetics (S.W., K.H., P.D.J.), and Laboratory of Neurogenetics, Institute Bora-Bunga (S.W., K.H., P.D.J.), University of Antwerp, Division of Neurology (P.D.J. and S.W.), Antwerp University Hospital, Belgium; Department of Paediatric Neurology (L.D.M.), University Hospital, Vrije Universiteit Brussel, Bruxelles, Belgium; Aix Marseille Université (M.M.), INSERM, GMGF UMR 910; APHM, Department de Gé- netique Medicale (C.B.), and Department de Génétique Medicale (T.B.), Hôpital d’Enfants de la Timone, Marseille, Génétique Clinique (M. L.), Chromosomique et Moleculaire, CHU Hôpital Nord, St Purçet en Jurass, Service de Génétique Médicale (C.F.), Centre Hospitalier Universitaire de Clermont-Ferrand, Département de Médecine Translationnelle et Neurogénétique (A.P.), IGBMC, CNRS UMR 7194/INSERM U964/ Université de Strasbourg, Illkirch; Laboratoire de Diagnostic Génétique (A.P.), Hôpitaux Universitaires de Strasbourg, France; CoGaT GmbH (E.R., S.B.), Tübingen, Germany; Swiss Epilepsy Center (E.R., H.V., T.D.), Zurich, Switzerland; Department of Neuropediatrics (I.H.), Uni- versity Medical Center Schleswig-Holstein, Kiel Campus, Germany; Cen- tre de Recherche du Centre Hospitalier Universitaire Sainte-Justine and Departments of Pediatrics and Neurosciences (I.J.M.), Université de Montréal, Canada; and the Department of General Paediatrics (S.S.), Division of Child Neurology and Inherited Metabolic Diseases, Centre for Paediatrics and Adolescents Medicine, University Hospital Heidelberg, Germany.

AUTHOR CONTRIBUTIONS
Study concept and design: Johannes R. Lemke, Bodo Laube, Steffen Sythe. Acquisition of data: Johannes R. Lemke, Kirsten Geider, Katherine L. Heibig, Hannah Schütz, Carolina Courage, Christel Depienne, Caroline Nava, Delphine Heron, Rikke S. Møller, Helle Hjalgrim, Dennis Lal, Bernd A. Neubauer, Peter Nürnberg, Holger Thiele, Gerhard Kurlemann, Geosuganne L. Arnold, Viksa Bambhani, Deborah Barthold, Christine Ramante J. Pedurupillay, Doviana Musco, Eirik Frengen, Perter Strommé, Dennis J. Dilgus, Emily S. Doherty, Emilie K. Bijlsma,
REFERENCES


**New! AAN Transforming Leaders Program**

Are you an established AAN member neurologist 10+ years out of residency who wants to move your career to the next level? Do you want to become a future leader at the AAN and in the field of neurology? Apply for the new, elite AAN Transforming Leaders Program by visiting AAN.com/view/ TransformingLeaders. Application deadline is July 1, 2016.

**Save These Dates for AAN CME Opportunities!**

Mark these dates on your calendar for exciting continuing education conferences by the American Academy of Neurology. Learn more at AAN.com/conferences.

**Sports Concussion Conference**
- July 8–10, 2016, Chicago, IL, at the Hilton Chicago

**Fall Conference**
- October 14–16, 2016, Las Vegas, NV, at the Cosmopolitan of Las Vegas

**20 Minutes Pack a Punch**

Neurology® Podcasts
- Interviews with top experts on new clinical research in neurology
- Editorial comments on selected articles
- Convenient—listen during your commute, at your desk, or even at the gym
- On demand—it’s there when you want it
- Fun and engaging
- New topic each week
- FREE

Listen now at www.aan.com/podcast
Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy
Johannes R. Lemke, Kirsten Geider, Katherine L. Helbig, et al.
Neurology 2016;86:2171-2178 Published Online before print May 6, 2016
DOI 10.1212/WNL.0000000000002740

This information is current as of May 6, 2016

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/86/23/2171.full">http://n.neurology.org/content/86/23/2171.full</a></th>
</tr>
</thead>
</table>
| Supplementary Material        | Supplementary material can be found at: http://n.neurology.org/content/suppl/2016/05/06/WNL.00000000000002
                                | 740.DC1                                                                                               |
| References                    | This article cites 23 articles, 4 of which you can access for free at: http://n.neurology.org/content/86/23/2171.full#ref-list-1 |
| Subspecialty Collections      | This article, along with others on similar topics, appears in the following collection(s): |
                                | All Epilepsy/Seizures http://n.neurology.org/cgi/collection/all_epilepsy_seizures |
                                | All Genetics http://n.neurology.org/cgi/collection/all_genetics |
                                | All Movement Disorders http://n.neurology.org/cgi/collection/all_movement_disorders |
                                | Developmental disorders http://n.neurology.org/cgi/collection/developmental_disorders |
                                | Ion channel gene defects http://n.neurology.org/cgi/collection/ion_channel_gene_defects |
| Permissions & Licensing       | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions |
| Reprints                      | Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise |

Neurology © is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.